Review Special Issues

β-Amyloid precursor protein (APP) and the human diseases

  • Several pathophysiological functions of the human β-amyloid precursor protein (APP) have been recently proposed in different human diseases such as neurodevelopmental and neurodegenerative disorders including rare diseases such as autism, fragile X syndrome, amyotrophic lateral sclerosis, multiple sclerosis, Lesch-Nyhan disease; common and complex disorders such as Alzheimer’s disease; metabolic disorders such as diabetes; and also cancer. APP as well as all of its proteolytic fragments including the amyloid-β (Aβ) peptide, are part of normal physiology. The targeting of the components of APP proteolytic processing as a pharmacologic strategy will not be without consequences. Recent research results highlight the impact of alternative splicing (AS) process on human disease, and may provide new directions for the research on the impact of the human APP on human diseases. The identification of molecules capable of correcting and/or inhibiting pathological splicing events is therefore an important issue for future therapeutic approaches. To this end, the defective APP-mRNA isoform responsible for the disease in cells and tissues appears as an ideal target for epigenetic therapeutic intervention and antisense drugs are potential treatment.

    Citation: Khue Vu Nguyen. β-Amyloid precursor protein (APP) and the human diseases[J]. AIMS Neuroscience, 2019, 6(4): 273-281. doi: 10.3934/Neuroscience.2019.4.273

    Related Papers:

    [1] Khue Vu Nguyen . Epigenetic modulation of human neurobiological disorders: Lesch-Nyhan disease as a model disorder. AIMS Neuroscience, 2025, 12(2): 58-74. doi: 10.3934/Neuroscience.2025005
    [2] Khue Vu Nguyen . Potential molecular link between the β-amyloid precursor protein (APP) and hypoxanthine-guanine phosphoribosyltransferase (HGprt) enzyme in Lesch-Nyhan disease and cancer. AIMS Neuroscience, 2021, 8(4): 548-557. doi: 10.3934/Neuroscience.2021030
    [3] Khue Vu Nguyen . Special Issue: Alzheimer’s disease. AIMS Neuroscience, 2018, 5(1): 74-80. doi: 10.3934/Neuroscience.2018.1.74
    [4] Khue Vu Nguyen . Encephalomalacia/gliosis, deep venous thrombosis, and cancer in Arg393His antithrombin Hanoi and the potential impact of the β-amyloid precursor protein (APP) on thrombosis and cancer. AIMS Neuroscience, 2022, 9(2): 175-215. doi: 10.3934/Neuroscience.2022010
    [5] Frank O. Bastian . Is Alzheimers Disease Infectious?
    Relative to the CJD Bacterial Infection Model of Neurodegeneration. AIMS Neuroscience, 2015, 2(4): 240-258. doi: 10.3934/Neuroscience.2015.4.240
    [6] Craig T. Vollert, Jason L. Eriksen . Microglia in the Alzheimers brain: a help or a hindrance?. AIMS Neuroscience, 2014, 1(3): 210-224. doi: 10.3934/Neuroscience.2014.3.210
    [7] Marco Calabrò, Carmela Rinaldi, Giuseppe Santoro, Concetta Crisafulli . The biological pathways of Alzheimer disease: a review. AIMS Neuroscience, 2021, 8(1): 86-132. doi: 10.3934/Neuroscience.2021005
    [8] Kiran Kumar Siddappaji, Shubha Gopal . Molecular mechanisms in Alzheimer's disease and the impact of physical exercise with advancements in therapeutic approaches. AIMS Neuroscience, 2021, 8(3): 357-389. doi: 10.3934/Neuroscience.2021020
    [9] Ubaid Ansari, Jimmy Wen, Burhaan Syed, Dawnica Nadora, Romteen Sedighi, Denise Nadora, Vincent Chen, Forshing Lui . Analyzing the potential of neuronal pentraxin 2 as a biomarker in neurological disorders: A literature review. AIMS Neuroscience, 2024, 11(4): 505-519. doi: 10.3934/Neuroscience.2024031
    [10] Ubaid Ansari, Vincent Chen, Romteen Sedighi, Burhaan Syed, Zohaer Muttalib, Khadija Ansari, Fatima Ansari, Denise Nadora, Daniel Razick, Forshing Lui . Role of the UNC13 family in human diseases: A literature review. AIMS Neuroscience, 2023, 10(4): 388-400. doi: 10.3934/Neuroscience.2023029
  • Several pathophysiological functions of the human β-amyloid precursor protein (APP) have been recently proposed in different human diseases such as neurodevelopmental and neurodegenerative disorders including rare diseases such as autism, fragile X syndrome, amyotrophic lateral sclerosis, multiple sclerosis, Lesch-Nyhan disease; common and complex disorders such as Alzheimer’s disease; metabolic disorders such as diabetes; and also cancer. APP as well as all of its proteolytic fragments including the amyloid-β (Aβ) peptide, are part of normal physiology. The targeting of the components of APP proteolytic processing as a pharmacologic strategy will not be without consequences. Recent research results highlight the impact of alternative splicing (AS) process on human disease, and may provide new directions for the research on the impact of the human APP on human diseases. The identification of molecules capable of correcting and/or inhibiting pathological splicing events is therefore an important issue for future therapeutic approaches. To this end, the defective APP-mRNA isoform responsible for the disease in cells and tissues appears as an ideal target for epigenetic therapeutic intervention and antisense drugs are potential treatment.


    In the recent few years, materials derived from natural renewable resources such as cellulose, chitosan, alginate, starch, collagen, elastin and gelatin have attracted much attention in various biomedical applications including scaffolds for tissue engineering, medical implants, vascular grafts, drug delivery, cancer targeting, cornea replacement, and biological detections [1,2,3]. Cellulose, a fascinating biopolymer, is by far the most abundant organic compound produced in the biosphere. It is biosynthesized by a variety of living organisms ranging from lower to higher plants, sea animals, bacteria and fungi. It is considered as an inexhaustive source of feedstock for the increasing demand for biocompatible and environmental friendly materials, products and devices. It is regularly regenerated by nature in relatively short period of time, where the bioproduction is estimated to be over 7.5 × 1010 metric tons annually [4,5]. Cellulose is commonly produced with a desired size by the top-down enzymatic, mechanical and/or chemical treatments of cellulosic precursors, in which cotton, wood, annual plants or other agricultural residues can be used. In contrast, cellulose can be obtained by a bottom-up approach, where cellulose is biosynthesized from glucose using the direct action of specific bacterial strains (e.g., K. xylinus) [6,7]. Owing to its physicochemical properties, renewability, biocompatibility, biodegradability, cellulose has served in a variety of applications during the past decades and continuously shows potential after adequate treatments (e.g., hydrolysis) or surface functionalization (e.g., grafting) [6,8], in several new applications such as electronic equipment, chemicals, automotive, spacecraft, energy storage in batteries and supercapacitors, and medical to cite a few [8]. Various suitable treatments have been developed to produce nanoscale cellulose [7]. Currently, the study of nanocellulose, material having at least one dimension in the nano-size (<100 nm), has attracted tremendous level of attention as revealed by the increasing number of scientific contributions and industrial investments in several fields [7,9,10]. The three-dimensional hierarchical structures that compose these cellulose nanofibers at different scales, the combination of the physicochemical properties of cellulose, together with the various advantages of nanomaterials (e.g., a high specific surface area, aspect ratio) open new opportunities in several fields, ranging from electronics to medical applications. These nanoscale celluloses have unique properties including high elastic modulus, dimensional stability, low thermal expansion coefficient, outstanding reinforcing potential, hydrogen-bonding capacity and eco-friendliness [7,9,10]. Nanocelluloses can be devided in numerous main categories: cellulose nanocrystals (CNC), cellulose nanofibrils (CNF), amorphous nanocellulose (ANC), Cellulose nanoyarn (CNY) and bacterial nanocellulose (BNC) [11]. Different approaches have been developed to produce nanoscale cellulose from several natural sources resulting in particles with different physicochemical and mechanical properties, crystallinities and surface chemistries. The key parameters of various nanocelluloses are displayed in Table 1 [7,8,9,10,11,12,13,14].

    Table 1. Types of cellulose nanofibers and their particle sizes.
    Terminology and nomenclature of nanocellulose Typical sources Approximate dimensions Advantageous properties
    Cellulose nanocrystals, nanocrystalline cellulose, cellulose nanocrystals Hardwood, Softwood, Annual plants/Agricultural residues, Bacteria, etc. 4–70 nm in width; 100–6000 nm in length Low density, low coefficient of thermal expansion, high tensile strength, high surface area, elongated morphology, ease of bioconjugation
    Cellulose nanofibril, nanofibrillar cellulose, nanofbrillated cellulose Hardwood, Softwood, Annual plants/Agricultural residues, Bacteria, etc. 20–100 nm in width; > 10,000 nm in length Large specific area, significant barrier, mechanical and colloidal properties, low density
    Bacterial nanocellulose, microbial nanocellulose Low molecular weight sugars 10–50 nm in width; > 1000 nm in length Unique nanostructure, purity, higher-dimensional stability, greater mechanical strength, greater capacity to hold water
    Amorphous cellulose Wood pulp, cotton 20–120 nm in width; 50–120 nm in length Increased content of functional groups and high sorption ability
    Cellulose nanoyarn Cellulose and cellulose derivatives 100–1000 nm in width; > 10,000 nm in length High surface area, high blotting ability
     | Show Table
    DownLoad: CSV

    The most important methodology to produce CNC is commonly based on acid hydrolysis, but currently several other procedures have been established [7]. These treatments can eliminate the disordered (amorphous) domains of purified cellulose fibers leaving behind the crystalline regions. The obtained CNC consists of elongated, cylindrical and rod like particles with widths and length of 4–70 nm and between 100 nm and several micrometers [12]. CNF, however, are usually obtained by delamination of cellulosic pulps through mechanical or combined treatments [9]. These nanofibers are flexible and have entangled network structure with a diameter of approximately 1–100 nm, and consisting of alternating crystalline and amorphous regions. More recently, many research works have focused on optimizing processes to lower energy consumption and other costs, and to improve quality, consistency, and yields [9]. On the other hand, BNC is typically obtained from bacteria (mainly Komagataeibacter xylinus), as a separate molecule and does not necessitate processing to eliminate contaminates. In the biosynthesis of BNC, the glucose chains are introduced inside the bacteria body and expelled out through minor pores existing on the cell wall. A 20–100 nm ribbon-shaped nanofibers with micrometer lengths, entangled to form stable network structures. BNC has opened several new applications such as immobilization of enzymes, bacteria and fungi, tissues engineering, heart valve prosthesis, artificial blood vessels, bone, cartilage, cornea and skin, and dental root treatment [10,15]. Another category, ANC, can be formed through acid hydrolysis of regenerated cellulose with subsequent ultrasound disintegration [11]. The prepared particles have spherical to elliptical shapes with diameters ranging from 80 to 120 nm, depending on the cellulose feedstock, isolation procedure and extraction conditions. Because of its amorphous structure, ANC exhibits specific characteristics, such as enhanced sorption, high accessibility, and increased functional group content. The main use of ANC is as carries for bioactive substances and thickening agent in different aqueous systems. CNY remains the less studied cellulosic nanofibers. It is commonly manufactured by electrospinning of a solution containing cellulose or cellulose derivative [11]. The produced eloctrospun nanofibers display diameters ranging from 100 to 1000 nm. CNY can be employed to create new types of wound dressings [16].

    Cellulosic nanofibers show great promise as a cost-effective advanced nanomaterial for biomedical and pharmaceutical applications owing to their biocompatibility, biodegradability, low cytotoxicity, high sorption and absorption ability, porosity, small dimensions, a variety of shapes and enhanced specific surface, surface chemistry, rheology, crystallinity, self-assembly, high thermal stability and desirable mechanical properties. They exhibit high chemical resistance to dilute solutions of acids and alkalis, organic solvents, proteolytic enzymes and antioxidants as well [8,11,17]. These applications can include medical implants, tissue engineering, drug delivery, wound healing, cardiovascular applications, and diagnostics [18]. Emerging fields being developed to use nanocelluloses and their composites in novel ways in biomedical applications such as 3D printing and magnetically responsive materials are currently until investigation [1]. Moreover, with their chemical functionality, cellulose nanofibers can be easily modified to yield useful products. Covalent modifications such as esterification, oxidation, eherification, silylation and polymer grafting, as well as non-covalent binding are suggested in the literature in order to get more interesting properties and increase the number of applications [1,2,18,19,20,21]. These properties are useful in scaffold design by improving mechanical properties, cell adhesion, proliferation, differentiation and cellular patterning, where various shapes can be obtained. Another hot topic is the application of cellulosic nanofibers materials for drug delivery in the form of tablet coating, membranes or bionanocomposite delivery systems. On the other hand, the production of cellulosic nanofibers aerogels with porous structure have demonstrated the potential for wound dressing and scaffolds. Fluorescent labeling of cellulosic nanofibers with various fluorophores is also of potential interest in bio-imaging, targeting and sensing uses.

    In summary, cellulosic nanofibers-based materials are now recognized as unique materials that can be employed to produce exceptional films, composites and gels that show interesting features as an alternative to petroleum-based materials with environmentally friendly and renewable characteristics. It is revealed that various nanocellulose-based materials and composites hold great promise in several biomedical applications. Even though various cellulose nanofibers have been demonstrated as nongenotoxic and noncytotoxic, further studies are required to completely address such issue. Chemical modification of the cellulosic structure to improve interactions with living tissues could enlarge the utilization of nanocelluloses in biomedical devices tremendously. However, the assessment of the potential risks attributed to this chemical modification is also needed, since each modification could result in drastic behavioral changes in cell–material interactions. Clearly, despite the significant developments concerning biomedical cellulose nanofibers-based materials, this area is still promising and intensive investigations necessitate to be performed. As materials science continues to rapidly develop in biomedical field, cellulose nanofibers may provide a promising solution in the future to overcome some of the insurmountable challenges of biomedical materials.


    Acknowledgments

    The author gratefully acknowledges the Ecole Militaire Polytechnique for the necessary facilities and encouragement for the accomplishment of this work.


    Conflict of interest

    The author declares that there are no conflicts of interest regarding the publication of this paper.




    Conflict of interest



    The author reports no conflicts of interest and has received no payment in preparation of this manuscript.

    [1] Nguyen KV (2018) Alzheimer's disease. AIMS Neuroscience 5: 74–80. doi: 10.3934/Neuroscience.2018.1.74
    [2] Zheng H, Koo EH (2006) The amyloid precursor protein: beyond amyloid. Mol Neurodegener 1: 5. doi: 10.1186/1750-1326-1-5
    [3] Nguyen KV (2015) The human β-amyloid precursor protein: biomolecular and epigenetic aspects. BioMol Concepts 6: 11–32.
    [4] Di Luca M, Colciaghi F, Pastorino L, et al. (2000) Platelets as a peripheral district where to study pathogenetic mechanisms of Alzheimer disease: The case of amyloid precursor protein. Eur J Pharmacol 405: 277–283. doi: 10.1016/S0014-2999(00)00559-8
    [5] Ray B, Long JM, Sokol DK, et al. (2011) Increased secreted amyloid precursor protein-α(sAPPα) in severe autism: proposal of a specific, anabolic pathway and putative biomarker. PLoS One 6: e20405. doi: 10.1371/journal.pone.0020405
    [6] Sokol DK, Maloney B, Long JM, et al. (2011) Autism, Alzheimer's disease, and fragile X, APP, FMRP, and mGluR5 are molecular links. Neurology 76: 1344–1352. doi: 10.1212/WNL.0b013e3182166dc7
    [7] Lahiri DK, Sokol DK, Erickson C, et al. (2013) Autism as early neurodevelopmental disorders: evidence for an sAPPα-mediated anabolic pathway. Front Cell Neurosci 7: 1–13.
    [8] Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. (2009) Advance in the treatment of fragile X syndrome. Pediatrics 123: 378–390. doi: 10.1542/peds.2008-0317
    [9] Bryson JB, Hobbs C, Parsons MJ, et al. (2012) Amyloid precursor protein (APP) contributes to pathology in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Hum Mol Genet 21: 3871–3882. doi: 10.1093/hmg/dds215
    [10] Gehrmann J, Banati RB, Cuzner ML, et al. (1995) Amyloid precursor protein (APP) expression in multiple sclerosis lesions. Glia 15: 141–151. doi: 10.1002/glia.440150206
    [11] Grant JL, Ghosn EE, Axtell RC, et al. (2012) Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med 4: 145ra 105.
    [12] Hohlfeld R, Wekerle H (2012) β-Amyloid: enemy or remedy. Sci Transl Med 4: 145fs24.
    [13] Chandra A (2015) Role of amyloid from a multiple sclerosis. Perspective: a literature review. Neuroimmunomodulation 22: 343–346.
    [14] Matias-Guiu JA, Oreja-Guevara C, Cabrera-Martin MN, et al. (2016) Amyloid proteins and their role in multiple sclerosis. Considerations in the use of amyloid-PET imaging. Front Neurol 7: 53.
    [15] Imamura A, Yamanouchi H, Kurokawa T, et al. (1992) Elevated fibrinopeptide A (FPA) in patients with Lesch-Nyhan syndrome. Brain Dev 14: 424–425. doi: 10.1016/S0387-7604(12)80355-X
    [16] Irbaz bin R, Muhammmad H, Huthayfa A (2014) Recurrent thrombosis in a patient with Lesch-Nyhan syndrome. Am J Med 127: e12.
    [17] Canobbio I, Visconte C, Momi S, et al. (2017) Platelet amyloid precursor protein is a modulator of venous thromboembolism in mice. Blood 130: 527–536. doi: 10.1182/blood-2017-01-764910
    [18] Nguyen KV (2014) Epigenetic regulation in amyloid precursor protein and the Lesch-Nyhan syndrome. Biochem Biophys Res Commun 446: 1091–1095. doi: 10.1016/j.bbrc.2014.03.062
    [19] Nguyen KV (2015) Epigenetic regulation in amyloid precursor protein with genomic rearrangements and the Lesch-Nyhan syndrome. Nucleosides Nucleotides Nucleic Acids 34: 674–690. doi: 10.1080/15257770.2015.1071844
    [20] Nguyen KV, Nyhan WL (2017) Quantification of various APP-mRNA isoforms and epistasis in Lesch-Nyhan disease. Neurosci Lett 643: 52–58. doi: 10.1016/j.neulet.2017.02.016
    [21] Hardy JA, Higgin GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184–185. doi: 10.1126/science.1566067
    [22] Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessonsrom the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 102–112.
    [23] Bettens K, Sleegers K, Van Broeckhoven C (2010) Current status on Alzheimer's disease molecular genetics: from past, to present, to future. Hum Mol Genet 19: R4–R11. doi: 10.1093/hmg/ddq142
    [24] Hampel H, Frank R, Broich K, et al. (2010) Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev 9: 560–574.
    [25] Jiang T, Yu JT, Zhu XC, et al. (2013) TREM2 in Alzheimer's disease. Mol Neurobiol 48: 180– 185. doi: 10.1007/s12035-013-8424-8
    [26] Ulrich JD, UllandTK, Colonna M, et al. (2017) Elucidating the role of TREM2 in Alzheimer's disease. Neuron 94: 237–248. doi: 10.1016/j.neuron.2017.02.042
    [27] Klafki HW (2006) Therapeutic approaches to Alzheimer's disease. Brain 129: 2840–2855. doi: 10.1093/brain/awl280
    [28] Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353–356. doi: 10.1126/science.1072994
    [29] Chetelat G (2013) Aβ-independent processes-rethinking preclinical AD. Nat Rev Neurol 9: 123–124. doi: 10.1038/nrneurol.2013.21
    [30] Wang SC, Oelze B, Schumacher A (2008) Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One 3: e2698. doi: 10.1371/journal.pone.0002698
    [31] Combarros O, Cortina-Borja M, Smith AD, et al. (2009) Epistasis in sporadic Alzheimer's disease. Neurobiol Aging 30: 1333–1349. doi: 10.1016/j.neurobiolaging.2007.11.027
    [32] Czeczor JK, McGee SL (2017) Emerging roles for the amyloid precursor protein and derived peptides in the regulation of cellular and systemic metabolism. J Neuroendocrinol 29: 1–8.
    [33] Aulston B, Schapansky J, HuangYW, et al. (2018) Secreted amyloid precursor protein alpha activates neuronal insulin receptor and prevents diabetes-induced encephalopathy. Exp Neurol 303: 29–37. doi: 10.1016/j.expneurol.2018.01.013
    [34] Moreno-Gonzalez I, Edwards III G, Salvadores N, et al. (2017) Molecular interaction between type 2 diabetes and Alzheimer's disease through cross-seeding of protein misfolding. Mol Psychiatry 22: 1327–1334. doi: 10.1038/mp.2016.230
    [35] Saitoh T, Sundsmo M, Roch JM, et al. (1989) Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblast. Cell 58: 615–622. doi: 10.1016/0092-8674(89)90096-2
    [36] Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283: 29615–29619. doi: 10.1074/jbc.R800019200
    [37] Zheng H, Koo EH (2011) Biology and pathology of the amyloid precursor protein. Mol Neurodegener 6: 27. doi: 10.1186/1750-1326-6-27
    [38] Roe CM, Fitzpatrick AL, Xiong C, et al. (2010) Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74: 106–112. doi: 10.1212/WNL.0b013e3181c91873
    [39] Hansel DE, Rahman A, Wehner S, et al. (2003) Increase expression and processing of the Alzheimer amyloid precursor protein in pancreatic cancer may influence cellular proliferation. Cancer Res 63: 7032–7037.
    [40] Takayama KI, Tsutsumi S, Suzuki T, et al. (2009) Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res 69: 137–142. doi: 10.1158/0008-5472.CAN-08-3633
    [41] Venkataramani V, Rossner C, Iffland L, et al. (2010) Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via dow-regulation of the Alzheimer amyloid precursor protein. J Biol Chem 285: 10678–10689. doi: 10.1074/jbc.M109.057836
    [42] Venkataramani V, Thiele K, Behnes CL, et al. (2012) Amyloid precursor protein is a biomarker for transformed human pluripotent stem cells. Am J Pathol 180: 1636–1652. doi: 10.1016/j.ajpath.2011.12.015
    [43] Takagi K, Ito S, Miyazaki T, et al. (2013) Amyloid precursor protein in human breast cancer: an androgen-induced gene associated with cell proliferation. Cancer Res 104: 1532–1538.
    [44] MiyazakiT, Ikeda K, Horie-Inoue K, et al. (2014) Amyloid precursor protein regulates migration and metalloproteinase gene expression in prostate cancer cells. Biochem Biophys Res Commun 452: 828–833. doi: 10.1016/j.bbrc.2014.09.010
    [45] Lim S, Yoo BK, Kim HS, et al. (2014) Amyloid-β precursor protein promotes cell proliferation and motility of advanced breast cancer. BMC Cancer 14: 928. doi: 10.1186/1471-2407-14-928
    [46] Pandey P, Sliker B, Peters HL, et al. (2016) Amyloid precursor protein and amyloid-precursor-like protein 2 in cancer. Oncotarget 7: 19430–19444.
    [47] Cordell HJ (2002) Epistasis: what it means, what it doesn't mean, and statistical method to detect it in humans. Hum Mol Genet 11: 2463–2468. doi: 10.1093/hmg/11.20.2463
    [48] Moore JH (2003) The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered 56: 73–82. doi: 10.1159/000073735
    [49] Riordan JD, Nadeau JH (2017) From peas to disease: modifier genes, network resilience, and the genetics of health. Am J Hum Genet 101: 177–191. doi: 10.1016/j.ajhg.2017.06.004
    [50] Pan Q, Shai O, Lee LJ, et al. (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40: 1413–1415. doi: 10.1038/ng.259
    [51] Faustino NA, Cooper TA (2003) Pre-mRNA splicing and human disease. Genes Dev 17: 419–437. doi: 10.1101/gad.1048803
    [52] Nguyen KV (2019) Potential epigenomic co-management in rare diseases and epigenetic therapy. Nucleosides Nucleotides Nucleic Acids 38: 752–780. doi: 10.1080/15257770.2019.1594893
    [53] Saonere JA (2011) Antisense therapy, a magic bullet for the treatment of various diseases: present and future prospects. J Med Genet Genom 3: 77–83.
  • This article has been cited by:

    1. Bharani Thangavelu, Bernard S. Wilfred, David Johnson, Janice S. Gilsdorf, Deborah A. Shear, Angela M. Boutté, Penetrating Ballistic-Like Brain Injury Leads to MicroRNA Dysregulation, BACE1 Upregulation, and Amyloid Precursor Protein Loss in Lesioned Rat Brain Tissues, 2020, 14, 1662-453X, 10.3389/fnins.2020.00915
    2. Luisa Galla, Nelly Redolfi, Tullio Pozzan, Paola Pizzo, Elisa Greotti, Intracellular Calcium Dysregulation by the Alzheimer’s Disease-Linked Protein Presenilin 2, 2020, 21, 1422-0067, 770, 10.3390/ijms21030770
    3. Khue Vu Nguyen, Robert K. Naviaux, William L. Nyhan, Lesch-Nyhan disease: I. Construction of expression vectors for hypoxanthine-guanine phosphoribosyltransferase (HGprt) enzyme and amyloid precursor protein (APP), 2020, 39, 1525-7770, 905, 10.1080/15257770.2020.1714653
    4. Jeanette A. M. Maier, Laura Locatelli, Giorgia Fedele, Alessandra Cazzaniga, André Mazur, Magnesium and the Brain: A Focus on Neuroinflammation and Neurodegeneration, 2022, 24, 1422-0067, 223, 10.3390/ijms24010223
    5. Sonia Podvin, Alexander Jones, Qing Liu, Brent Aulston, Charles Mosier, Janneca Ames, Charisse Winston, Christopher B. Lietz, Zhenze Jiang, Anthony J. O’Donoghue, Tsuneya Ikezu, Robert A. Rissman, Shauna H. Yuan, Vivian Hook, Mutant Presenilin 1 Dysregulates Exosomal Proteome Cargo Produced by Human-Induced Pluripotent Stem Cell Neurons, 2021, 6, 2470-1343, 13033, 10.1021/acsomega.1c00660
    6. Carmela Matrone, The paradigm of amyloid precursor protein in amyotrophic lateral sclerosis: The potential role of the 682YENPTY687 motif, 2023, 21, 20010370, 923, 10.1016/j.csbj.2023.01.008
    7. Anthony M Kyriakopoulos, Greg Nigh, Peter A McCullough, Stephanie Seneff, Mitogen Activated Protein Kinase (MAPK) Activation, p53, and Autophagy Inhibition Characterize the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein Induced Neurotoxicity, 2022, 2168-8184, 10.7759/cureus.32361
    8. Nourhan Mohammad Abd Abd El-Aziz, Mohamed Gamal Shehata, Tawfiq Alsulami, Ahmed Noah Badr, Marwa Ramadan Elbakatoshy, Hatem Salama Ali, Sobhy Ahmed El-Sohaimy, Characterization of Orange Peel Extract and Its Potential Protective Effect against Aluminum Chloride-Induced Alzheimer’s Disease, 2022, 16, 1424-8247, 12, 10.3390/ph16010012
    9. Kaoru Sato, Ken-ichi Takayama, Makoto Hashimoto, Satoshi Inoue, Transcriptional and Post-Transcriptional Regulations of Amyloid-β Precursor Protein (APP) mRNA, 2021, 2, 2673-6217, 10.3389/fragi.2021.721579
    10. Hari Shanker Sharma, Dafin F. Muresanu, Rudy J. Castellani, Ala Nozari, José Vicente Lafuente, Anca D. Buzoianu, Seaab Sahib, Z. Ryan Tian, Igor Bryukhovetskiy, Igor Manzhulo, Preeti K. Menon, Ranjana Patnaik, Lars Wiklund, Aruna Sharma, 2021, 265, 9780323901628, 1, 10.1016/bs.pbr.2021.04.008
    11. Khue Vu Nguyen, Potential molecular link between the β-amyloid precursor protein (APP) and hypoxanthine-guanine phosphoribosyltransferase (HGprt) enzyme in Lesch-Nyhan disease and cancer, 2021, 8, 2373-7972, 548, 10.3934/Neuroscience.2021030
    12. Tamara Žigman, Danijela Petković Ramadža, Goran Šimić, Ivo Barić, Inborn Errors of Metabolism Associated With Autism Spectrum Disorders: Approaches to Intervention, 2021, 15, 1662-453X, 10.3389/fnins.2021.673600
    13. Olivier Dionne, François Corbin, An “Omic” Overview of Fragile X Syndrome, 2021, 10, 2079-7737, 433, 10.3390/biology10050433
    14. Xiao‐Ming Wang, Peng Zeng, Ying‐Yan Fang, Teng Zhang, Qing Tian, Progranulin in neurodegenerative dementia, 2021, 158, 0022-3042, 119, 10.1111/jnc.15378
    15. Zeba Firdaus, Xiaogang Li, Epigenetic Explorations of Neurological Disorders, the Identification Methods, and Therapeutic Avenues, 2024, 25, 1422-0067, 11658, 10.3390/ijms252111658
    16. Smita Jain, Ankita Murmu, Saraswati Patel, Elucidating the therapeutic mechanism of betanin in Alzheimer’s Disease treatment through network pharmacology and bioinformatics analysis, 2024, 39, 1573-7365, 1175, 10.1007/s11011-024-01385-w
    17. Yao-Bo Li, Qiang Fu, Mei Guo, Yang Du, Yuewen Chen, Yong Cheng, MicroRNAs: pioneering regulators in Alzheimer’s disease pathogenesis, diagnosis, and therapy, 2024, 14, 2158-3188, 10.1038/s41398-024-03075-8
    18. Salva Afshari, Mehdi Sarailoo, Vahid Asghariazar, Elham Safarzadeh, Masoomeh Dadkhah, Persistent diazinon induced neurotoxicity: The effect on inhibitory avoidance memory performance, amyloid precursor proteins, and TNF-α levels in the prefrontal cortex of rats, 2024, 43, 0960-3271, 10.1177/09603271241235408
    19. Siding Chen, Zhe Xu, Jinfeng Yin, Hongqiu Gu, Yanfeng Shi, Cang Guo, Xia Meng, Hao Li, Xinying Huang, Yong Jiang, Yongjun Wang, Predicting functional outcome in ischemic stroke patients using genetic, environmental, and clinical factors: a machine learning analysis of population-based prospective cohort study, 2024, 25, 1467-5463, 10.1093/bib/bbae487
    20. Ana Luiza Guimarães Reis, Jessica Ruivo Maximino, Luis Alberto de Padua Covas Lage, Hélio Rodrigues Gomes, Juliana Pereira, Paulo Roberto Slud Brofman, Alexandra Cristina Senegaglia, Carmen Lúcia Kuniyoshi Rebelatto, Debora Regina Daga, Wellingson Silva Paiva, Gerson Chadi, Proteomic analysis of cerebrospinal fluid of amyotrophic lateral sclerosis patients in the presence of autologous bone marrow derived mesenchymal stem cells, 2024, 15, 1757-6512, 10.1186/s13287-024-03820-2
    21. Hye Kyung Jeon, Hae Young Yoo, Ashish Verma, Single-nucleotide polymorphisms link gout with health-related lifestyle factors in Korean cohorts, 2023, 18, 1932-6203, e0295038, 10.1371/journal.pone.0295038
    22. Paras Mani Giri, Anurag Banerjee, Arpita Ghosal, Buddhadev Layek, Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications, 2024, 25, 1422-0067, 3995, 10.3390/ijms25073995
    23. Sungtaek Oh, Yura Jang, Chan Hyun Na, Discovery of Biomarkers for Amyotrophic Lateral Sclerosis from Human Cerebrospinal Fluid Using Mass-Spectrometry-Based Proteomics, 2023, 11, 2227-9059, 1250, 10.3390/biomedicines11051250
    24. Amirreza Gholami, Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches, 2023, 817, 03043940, 137532, 10.1016/j.neulet.2023.137532
    25. Angelika Buczyńska, Iwona Sidorkiewicz, Adam Jacek Krętowski, Monika Zbucka-Krętowska, The Role of Oxidative Stress in Trisomy 21 Phenotype, 2023, 43, 0272-4340, 3943, 10.1007/s10571-023-01417-6
    26. Yingchun Liu, Yuman Fan, Rongbin Gong, Moqin Qiu, Xiaoxia Wei, Qiuling Lin, Zihan Zhou, Ji Cao, Yanji Jiang, Peiqin Chen, Bowen Chen, Xiaobing Yang, Yuying Wei, RuoXin Zhang, Qiuping Wen, Hongping Yu, Novel genetic variants in the NLRP3 inflammasome-related PANX1 and APP genes predict survival of patients with hepatitis B virus-related hepatocellular carcinoma, 2024, 1699-3055, 10.1007/s12094-024-03634-x
    27. Sonali Sundram, Neerupma Dhiman, Rishabha Malviya, Rajendra Awasthi, Non-coding RNAs in Regulation of Protein Aggregation and Clearance Pathways: Current Perspectives Towards Alzheimer's Research and Therapy, 2024, 24, 15665232, 8, 10.2174/1566523223666230731093030
    28. Zhifang Wang, Jingpei Zhou, Bin Zhang, Zhanqiong Xu, Haoyu Wang, Quan Sun, Nanbu Wang, Inhibitory effects of β-asarone on lncRNA BACE1-mediated induction of autophagy in a model of Alzheimer’s disease, 2024, 463, 01664328, 114896, 10.1016/j.bbr.2024.114896
    29. Arezoo Mirzaie, Hassan Nasrollahpour, Balal Khalilzadeh, Ali Akbar Jamali, Raymond J. Spiteri, Hadi Yousefi, Ibrahim Isildak, Reza Rahbarghazi, Cerebrospinal fluid: A specific biofluid for the biosensing of Alzheimer's diseases biomarkers, 2023, 166, 01659936, 117174, 10.1016/j.trac.2023.117174
    30. Huda R. Kammona, Thair M. Farhan, Haider J. Mubarak, Bassim I. Mohammad, Najah R. Hadi, Hussein A. Abid, Anil K. Philip, Dina, A. Jamil, Hayder A. Al-Aubaidy, Impact of prenatal tramadol exposure on cerebral and cerebellar development and amyloid precursor protein expression in newborn mice, 2024, 31, 2576-5299, 310, 10.1080/25765299.2024.2355696
    31. Grażyna Pyka-Fościak, Ewa Jasek-Gajda, Bożena Wójcik, Grzegorz J. Lis, Jan A. Litwin, Tau Protein and β-Amyloid Associated with Neurodegeneration in Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis (EAE), a Mouse Model of Multiple Sclerosis, 2024, 12, 2227-9059, 2770, 10.3390/biomedicines12122770
    32. Catherine Zhu, Younghun Han, Jinyoung Byun, Xiangjun Xiao, Simon Rothwell, Frederick W. Miller, Ingrid E. Lundberg, Peter K. Gregersen, Jiri Vencovsky, Vikram R. Shaw, Neil McHugh, Vidya Limaye, Albert Selva‐O'Callaghan, Michael G. Hanna, Pedro M. Machado, Lauren M. Pachman, Ann M. Reed, Lisa G. Rider, Øyvind Molberg, Olivier Benveniste, Timothy Radstake, Andrea Doria, Jan L. De Bleecker, Boel De Paepe, Britta Maurer, William E. Ollier, Leonid Padyukov, Lucy R. Wedderburn, Hector Chinoy, Janine A. Lamb, Christopher I. Amos, Genetic Architecture of Idiopathic Inflammatory Myopathies From Meta‐Analyses, 2025, 2326-5191, 10.1002/art.43088
    33. Kashif Abbas, Mohd Mustafa, Mudassir Alam, Safia Habib, Waleem Ahmad, Mohd Adnan, Md. Imtaiyaz Hassan, Nazura Usmani, Multi-target approach to Alzheimer’s disease prevention and treatment: antioxidant, anti-inflammatory, and amyloid- modulating mechanisms, 2025, 26, 1364-6753, 10.1007/s10048-025-00821-y
    34. Vaghawan Prasad Ojha, Sheida Riahi, Richard Hunt Bobo, Seyedadel Moravveji, Lucien Meteumba, Shantia Yarahmadian, Analysis of cognitive status of Alzheimer’s disease’s subjects and its association with biomarkers (amyloid beta and tau proteins) using NACC data, 2025, 5, 2731-4537, 10.1007/s44202-025-00335-6
    35. Rui Wang, Juan Li, Xiaochen Li, Yan Guo, Pei Chen, Tian Peng, Exercise-induced modulation of miRNAs and gut microbiome: a holistic approach to neuroprotection in Alzheimer’s disease, 2025, 0334-1763, 10.1515/revneuro-2025-0013
    36. Pinar Peyvand, Pantea Allami, Nima Rezaei, From genetic roots to recent advancements in gene therapy targeting amyloid beta in Alzheimer’s disease, 2025, 0334-1763, 10.1515/revneuro-2025-0025
  • Reader Comments
  • © 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(6200) PDF downloads(687) Cited by(36)

Article outline

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog